Nexsen Limited logo

Nexsen Limited (NXN)

Market Open
ASX ASX
51.05M Market Cap
- P/E Ratio
- Div Yield
454,806 Volume
- Eps
Want to track NXN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NXN is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on ASX (AUD).

Nexsen Limited (NXN) FAQ

On which exchange is it traded?

Nexsen Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is NXN.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 51.05M.

Has Nexsen Limited ever had a stock split?

No, there has never been a stock split.

Nexsen Limited Profile

- Industry
- Sector
- CEO
ASX Exchange
AU0000418782 ISIN
Australia Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Nexsen Limited is a biotechnology company dedicated to advancing healthcare through innovative nanobiotechnology platforms that facilitate rapid and high-precision diagnostic and sensing applications. Founded in 2021 and based in Sydney, Australia, the company is at the forefront of revolutionizing diagnostics within the healthcare sector. Its mission is to develop lab-quality diagnostic solutions that deliver results in mere minutes, directly at the point of care or use, thereby removing the dependency on conventional laboratory infrastructures.

The company's diverse technology portfolio is crafted to cater to various critical diagnostic needs, extending its reach beyond human medical diagnostics to include veterinary, agricultural, and biosecurity applications. By employing a modular approach that harnesses advanced materials, biomarker discovery, and machine learning, Nexsen Limited aims to produce scalable and user-friendly devices known for their high sensitivity and operational ease. This strategic positioning reflects the growing significance of biotechnology in modern diagnostics and public health solutions, as Nexsen Limited endeavors to improve access to vital health and safety information across multiple sectors.

Products and Services

  • Biosensing Solutions for Human Medical Diagnostics:

    Nexsen Limited provides innovative biosensing technologies designed for rapid human diagnostics, facilitating quick and accurate results that empower decision-making in clinical settings.

  • Tests for Group B Streptococcus (GBS):

    This diagnostic test allows for prompt identification of Group B Streptococcus in expectant mothers, which is crucial for preventing severe infections in newborns during delivery.

  • Diagnostics for Chronic and Acute Kidney Disease:

    Nexsen offers targeted tests aimed at early detection of kidney diseases, enabling timely interventions that can significantly enhance patient outcomes and reduce healthcare costs.

  • Solutions for Bovine Mastitis:

    In the veterinary sector, Nexsen develops rapid diagnostic tests for bovine mastitis, aiding farmers in swiftly managing herd health and improving milk production quality.

  • Diagnostics for Biosecurity Pathogens:

    The company’s offerings include tests for various biosecurity pathogens, ensuring effective monitoring and response measures to protect public health and agricultural integrity.

Contact Information

Address: 4 Bridge Street
Phone: 61 2 9174 5388